|
Market Closed -
OTC Markets
08:27:58 03/06/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -2.09% |
|
+5.04% | -87.61% |
| 14/08 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 14/08 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 26.75L 23.96L 22.04L 19.97L 37.32L 25Cr 38.02L 2.63Cr 1.05Cr 13Cr 1Cr 98.25L 42Cr | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 2.45Cr 2.2Cr 2.02Cr 1.83Cr 3.42Cr 232.9Cr 3.49Cr 24Cr 9.67Cr 122.51Cr 9.21Cr 9.01Cr 386.36Cr | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.09% | ||
| 1 week | +5.04% | ||
| Current month | -8.20% | ||
| 1 month | -8.20% | ||
| 3 months | -18.25% | ||
| 6 months | -29.80% | ||
| Current year | -87.61% |
| 1 week | 0.1 |  | 0.13 |
| 1 month | 0.1 | | 0.13 |
| Current year | 0.05 | | 1.2 |
| 1 year | 0.05 | | 1.48 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 11.7 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 21/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 16/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 01/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 01/04/2013 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 21/03/2023 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 21/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/03/26 | Emerging Technology Partners LLC
| Other | Company | 10,97,341 | 7.0830% | |
| 18/03/26 | Panacea Venture
| Other | Company | 45,29,956 | 29.2393% | |
| 18/03/26 | Other | Chief Financial Officer | 75,000 | 0.4841% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.09% | +5.04% | -92.26% | -97.08% | 26.75L | |
| +3.19% | +11.31% | +67.86% | +150.58% | 1,26300Cr | |
| -0.73% | +3.56% | +44.51% | +85.81% | 66TCr | |
| +1.41% | +3.24% | +29.22% | +107.83% | 52TCr | |
| +0.42% | +3.20% | +54.15% | +67.18% | 39TCr | |
| +2.18% | +2.93% | +73.30% | +45.62% | 37TCr | |
| +1.12% | +4.52% | +35.30% | +58.08% | 31TCr | |
| +6.96% | +8.86% | +11.27% | +36.62% | 29TCr | |
| +1.15% | +6.09% | +59.59% | +77.06% | 25TCr | |
| +3.06% | +9.38% | +44.11% | +119.47% | 21TCr | |
| Average | +1.35% | +5.31% | +32.70% | +65.12% | 42.62TCr | |
| Weighted average by Cap. | +1.19% | +6.60% | +50.88% | +98.31% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.85Cr 2.56Cr 2.35Cr 2.13Cr 3.98Cr 270.96Cr 4.06Cr 28Cr 11Cr 142.53Cr 11Cr 10Cr 449.5Cr | 2.07Cr 1.85Cr 1.71Cr 1.55Cr 2.89Cr 196.66Cr 2.94Cr 20Cr 8.17Cr 103.45Cr 7.77Cr 7.61Cr 326.24Cr |
| Net income | -3.93Cr -3.52Cr -3.23Cr -2.93Cr -5.48Cr -372.76Cr -5.58Cr -39Cr -15Cr -196.08Cr -15Cr -14Cr -618.37Cr | -4.81Cr -4.3Cr -3.96Cr -3.59Cr -6.71Cr -456.31Cr -6.83Cr -47Cr -19Cr -240.03Cr -18Cr -18Cr -756.98Cr |
| Net Debt | 60.5L 54.18L 49.84L 45.16L 84.41L 57Cr 85.99L 5.94Cr 2.39Cr 30Cr 2.27Cr 2.22Cr 95Cr | 2.19Cr 1.96Cr 1.8Cr 1.63Cr 3.05Cr 207.51Cr 3.11Cr 21Cr 8.62Cr 109.15Cr 8.2Cr 8.03Cr 344.23Cr |
Employees
214
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $0.1301 | +14.18% | 258 |
| 29/26/29 | $0.1140 | +13.96% | 11,522 |
| 27/26/27 | $0.1000 | -.--% | 252 |
| 26/26/26 | $0.1000 | -0.25% | 640 |
| 23/26/23 | $0.1003 | +0.15% | 4,142 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
Select your edition
All financial news and data tailored to specific country editions
